A phase 2 study of XL999 in subjects With relapsed/refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphony Evolution
- 27 Jun 2007 Status changed from suspended to discontinued.
- 06 Nov 2006 Status change
- 31 Jan 2006 New trial record.